在阿尔茨海默病中改善认知功能和功能独立:专业痴呆症护理的作用
Guoyan Liu1, Mei Xu1
1Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Neurological research
|January 30, 2026
概括
专业痴呆症护理显著改善了阿尔茨海默病患者的认知功能,自我护理和生活质量. 这种方法也提高了心理性和整体护理满意度.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 护理科学 护理科学
背景情况:
- 阿尔茨海默病 (AD) 对患者的认知功能,自我护理能力和整体生活质量构成重大挑战.
- 现有的护理护理模式可能无法完全满足阿兹海默症患者的多方面的需求,需要创新的方法.
研究的目的:
- 评估专业痴呆症护理计划对阿兹海默症患者的认知功能,自我护理能力,心理状态和生活质量的影响.
- 为了比较专业护理护理与常规护理护理在AD患者队列中的有效性.
主要方法:
- 一组131名AD患者被分为对照组 (常规护理,n=58) 和干预组 (常规护理加上专业护理,n=73).
- 包括认知功能 (MMSE,ADAS-Cog),自我照顾能力 (ADL,ESCA),心理状态 (HAMA,HAMD,CD-RISC),生活质量 (DQOL) 和护理满意度在内的关键结果被评估和组之间比较.
主要成果:
- 干预组表现出显著的改善,包括认知功能 (MMSE,ADCS-ADL),自我照顾能力 (ADL,ESCA) 和心理弹性 (CD-RISC) 的更高得分.
- 与对照组相比,干预组的焦虑和抑郁分数 (HAMA,HAMD) 显著降低,生活质量改善 (DQOL).
- 在专门护理小组中,护理满意度显著更高.
结论:
- 专门的痴呆症护理有效地提高了阿尔茨海默病患者的认知功能,自我护理能力,心理性和生活质量.
- 这种专门的方法导致患者对护理的满意度增加,这表明其在临床实践中的价值.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:30Dementia
696
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
696
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35